IceCure Medical Statistics
Total Valuation
IceCure Medical has a market cap or net worth of $48.63 million. The enterprise value is $39.93 million.
Important Dates
The last earnings date was Tuesday, March 17, 2026, before market open.
| Earnings Date | Mar 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IceCure Medical has 73.12 million shares outstanding. The number of shares has increased by 24.97% in one year.
| Current Share Class | 68.96M |
| Shares Outstanding | 73.12M |
| Shares Change (YoY) | +24.97% |
| Shares Change (QoQ) | +11.05% |
| Owned by Insiders (%) | 40.42% |
| Owned by Institutions (%) | 0.82% |
| Float | 41.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.39 |
| Forward PS | 9.45 |
| PB Ratio | 5.37 |
| P/TBV Ratio | 5.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.61 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -188.78% and return on invested capital (ROIC) is -113.56%.
| Return on Equity (ROE) | -188.78% |
| Return on Assets (ROA) | -71.29% |
| Return on Invested Capital (ROIC) | -113.56% |
| Return on Capital Employed (ROCE) | -166.53% |
| Weighted Average Cost of Capital (WACC) | 16.68% |
| Revenue Per Employee | $51,197 |
| Profits Per Employee | -$228,136 |
| Employee Count | 66 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 0.93 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.17% in the last 52 weeks. The beta is 2.27, so IceCure Medical's price volatility has been higher than the market average.
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -53.17% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 55.01 |
| Average Volume (20 Days) | 286,081 |
Short Selling Information
The latest short interest is 611,285, so 0.84% of the outstanding shares have been sold short.
| Short Interest | 611,285 |
| Short Previous Month | 624,994 |
| Short % of Shares Out | 0.84% |
| Short % of Float | 1.49% |
| Short Ratio (days to cover) | 3.33 |
Income Statement
In the last 12 months, IceCure Medical had revenue of $3.38 million and -$15.06 million in losses. Loss per share was -$0.24.
| Revenue | 3.38M |
| Gross Profit | 1.23M |
| Operating Income | -15.09M |
| Pretax Income | -15.06M |
| Net Income | -15.06M |
| EBITDA | -14.80M |
| EBIT | -15.09M |
| Loss Per Share | -$0.24 |
Full Income StatementBalance Sheet
The company has $8.90 million in cash and $204,000 in debt, with a net cash position of $8.69 million or $0.12 per share.
| Cash & Cash Equivalents | 8.90M |
| Total Debt | 204,000 |
| Net Cash | 8.69M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 9.05M |
| Book Value Per Share | 0.12 |
| Working Capital | 7.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.57 million and capital expenditures -$36,000, giving a free cash flow of -$14.61 million.
| Operating Cash Flow | -14.57M |
| Capital Expenditures | -36,000 |
| Free Cash Flow | -14.61M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
| Gross Margin | 36.28% |
| Operating Margin | -446.70% |
| Pretax Margin | -445.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IceCure Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.97% |
| Shareholder Yield | -24.97% |
| Earnings Yield | -30.96% |
| FCF Yield | -30.05% |
Analyst Forecast
The average price target for IceCure Medical is $2.50, which is 275.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.50 |
| Price Target Difference | 275.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 79.23% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
